secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2023-04-12T23:59:59+00:00
Accession:  0001213900-23-029177
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 2.03, 3.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics receives Nasdaq delisting notice; additional $350K note from 3i
--------------------------------------------------------------------------------

- Nasdaq notified the company on April 11, 2023 that it failed to meet extension terms for minimum $10M equity rule; delisting set for April 20 unless appeal.
- Company reported stockholders' equity of ~$8.0M as of June 30, 2022, below the $10M continued listing requirement.
- Entered first amendment allowing additional note purchases from 3i, LP; on April 11, 3i purchased a $350,000 secured promissory note.
- Total principal outstanding under the notes is $2,666,640; new notes bear 5% interest, mature Jan 1, 2024, and are secured by all assets.
- Company intends to appeal the delisting determination to Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023029177/0001213900-23-029177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023029177/ea176859-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-029177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer